Drug intelligence / Profile preview

PEG-encapsulated allogeneic islet cells

Development stage
Unknown
Lead developer
Eli Lilly
Modality
Cell Therapies, Hydrogel Systems → Drug Delivery Systems
Administration
Implant
01

Overview

PEG-encapsulated allogeneic islet cells represent a cell-based therapeutic platform designed for the treatment of Type 1 Diabetes. The technology involves the transplantation of donor-derived (allogeneic) pancreatic islet cells that have been encapsulated within a biocompatible polyethylene glycol (PEG) hydrogel or conformal coating. This PEG layer acts as a semi-permeable physical barrier, allowing for the physiological diffusion of glucose, oxygen, and insulin while shielding the transplanted cells from the recipient's immune system, including T-cell mediated rejection and autoantibody attacks. The primary objective of this immunoisolation strategy is to achieve long-term graft survival and functional insulin independence without the requirement for chronic systemic immunosuppression, which is the major limitation of conventional islet transplantation.

Other names
PEG-encapsulated isletsencapsulated allogeneic isletsPEG-coated isletsPEG-encapsulated allogeneic pancreatic islet cells

Beyond the preview

Go deeper on PEG-encapsulated allogeneic islet cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on PEG-encapsulated allogeneic islet cells.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call